Just a reminder. NWBO have never said they were in a quiet period in regard to TLD/Publication because of fear of attacks. That is a theory developed here among retail share holders. I believe it is partly the reason, but in general, they are likely doing it on advice of counsel, based on the past. It is easier to avoid any frivolous law suits by simply not making any statements as to the status of the results. They are making statements about anything other than TLD, as we have seen with the Sawston Cert. They have only laid out the process for releasing TLD and that they wanted it to be in connection with a journal article. It is not like they have gone dark. They are just saying that you will see the results in a TLD PR, followed by publication.
If anyone care to read their financials, they have explained that there is a delay due to Covid. I understand that some posters do not find that as a valid reason, but that is what they have told us. Based on my experience with Academia, I don't doubt their excuse is valid.
I am 99% sure that the change in direction from their August 20 PR regarding expecting TLD shortly, when they realized that RA's were going to agree to use external controls. I am also pretty certain that the changing endpoints and the change in the definition of GBM has added substantially to the delay. Getting reviewers onboard with this ground breaking set-up has likely been a hard fought fight as well.
I was told by a biotech expert that the hold=up could possibly be the Journal that needs more certainty as to the FDA views on new set-up.
Good luck and I hope you all don't lose your mind waiting for the results (Too late for some, but there's still a bunch of posters that can be saved)
